Third Harmonic Bio Inc expected to post a loss of 34 cents a share - Earnings Preview

Third Harmonic Bio

21/03/2025 12:43

Third Harmonic Bio Inc THRD.OQ THRD.O is expected to show no change in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Third Harmonic Bio Inc is for a loss of 34 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Third Harmonic Bio Inc is $5.25​, above​ its last closing price of $3.55. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.30
-0.30
-0.33
Missed
-10.4
Jun. 30 2024
-0.24
-0.27
-0.26
Beat
3.7
Mar. 31 2024
-0.30
-0.31
-0.20
Beat
35.3​
Dec. 31 2023
-0.31
-0.17
Beat
45.2
​​Sep. 30 2023
-0.27
-0.27
-0.19
Beat
29.6
Jun. 30 2023
-0.30
-0.30
-0.19
Beat
36.7​
Mar. 31 2023
-0.35
-0.35
-0.40
Missed
-14.3
Dec. 31 2022
-0.71
-0.47
-0.36
Beat
23.4

This summary was machine generated March 21 at 12:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)